We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
733-P: A Randomized Controlled Trial Comparing Insulin Degludec U100 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients with Type 2 Diabetes: Degludec Hospital Trial.
- Authors
GALINDO, RODOLFO J.; PASQUEL, FRANCISCO J.; VELLANKI, PRIYATHAMA; ALICIC, RADICA Z.; LAM, DAVID W.; FAYFMAN, MAYA; MIGDAL, ALEXANDRA; URRUTIA, MARIA A.; DAVIS, GEORGIA; CARDONA, SAUMETH; ZAMUDIO, KARLA W.; ALBURY, BONNIE S.; PEREZ-GUZMAN, MIREYA C.; PENG, LIMIN; UMPIERREZ, GUILLERMO E.
- Abstract
Limited data exist about the use of insulin degludec in the hospital. This prospective, open-label, randomized clinical trial compared the efficacy and safety of a basal-bolus regimen using degludec U100 or glargine U100 for the management of patients with T2D. A total of 181 general medicine and surgery patients (age: 56±11, diabetes duration: 13.0±9.2 years) with an admission BG: 140-400 mg/dL and treated with oral agents or insulin prior to admission were randomized to degludec (n=93) or glargine (n=88). Total daily insulin dose started at 0.4 U/kg/d for BG: 140-200 mg/dL or 0.5 U/kg/d for BG: 201-400 mg/dL half dose given as basal (degludec or glargine) once daily and half as prandial (aspart) before meals. Insulin was adjusted daily to a target BG before meals between 70-180 mg/dL. The primary outcome was a difference in mean daily BG during the hospital stay. For the entire cohort, the BG at randomization was 218.6±52 mg/dL and HbA1c: 9.79±2.0% [mean±SD]. There were no differences in mean daily BG (180.1±38 vs. 180.0±45 mg/dL, p=0.9), proportion of BG in target range of 70-180 mg/dL (54.5±29% vs. 55.3±28%, p=0.85), total daily insulin dose (56±24 vs. 59±36 units/day, p=0.92), basal insulin (29.6±13 vs. 30.4±18 units/day, p=0.85), length of stay (median (IQR): 6.7 (4.7-10.5) vs. 7.5 (4.7,11.6) days, p=0.61), hospital complications (23% vs. 23%, p=0.95), or treatment failures ([mean daily BG>240 mg/dL or >2 consecutive BG>240 mg/dL] 9.8% vs. 13%, p=0.62) between degludec and glargine. There were no differences in the proportion of patients with BG <70 mg/dL (17% vs. 19%, p=0.75) or <54 mg/dL (3.7% vs. 1.3%, p=0.62) between degludec and glargine, with no patients having a BG<40mg/dL. In summary, our study indicates that hospital treatment with degludec U100 or glargine U100 is equally effective and safe in improving glycemic control in general medicine and surgery patients with T2D. Disclosure: R. J. Galindo: Consultant; Self; Abbott Diabetes, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi US, Valeritas, Inc., Research Support; Self; Dexcom, Inc., Novo Nordisk. S. Cardona: None. K. W. Zamudio: None. B. S. Albury: None. M. C. Perez-guzman: None. L. Peng: None. G. E. Umpierrez: Research Support; Self; AstraZeneca, Dexcom, Inc., Novo Nordisk. F. J. Pasquel: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Research Support; Self; Dexcom, Inc., Merck & Co., Inc. P. Vellanki: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc. R. Z. Alicic: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc. D. W. Lam: None. M. Fayfman: None. A. Migdal: None. M. A. Urrutia: None. G. Davis: None. Funding: Novo Nordisk
- Publication
Diabetes, 2021, Vol 70, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db21-733-P